ART27.13 — Safety, Research, Risks & Legal Status

Not medical advice. ART27.13 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	ART27.13; Artelo-27.13; AstraZeneca-derived cannabinoid agonist (no approved brand name)
Category	Research Chemical
Developer	Artelo Biosciences (NASDAQ: ARTL); originally derived from AstraZeneca research
Structural class	Benzimidazole derivative; novel synthetic cannabinoid receptor agonist
Receptor targets	Peripheral CB1 and CB2 GPCRs; designed for minimal CNS penetration
Primary indication under study	Cancer-related anorexia-cachexia syndrome (CACS); no FDA-approved treatment exists for this condition
Highest dose tested (Phase 2)	1,300 µg/day; no dose-limiting toxicities reported through 12 weeks
Trial registry	EudraCT-2020-000464-27 (CAReS); 18 sites across five countries
US legal status	Investigational drug — unapproved by the FDA. ART27.13 is currently in Phase 1/2 clinical development and has no approved indication in the United States or elsewhere. It is not legally available for human use outside of an approved clinical trial protocol. No OTC, supplement, or gray-market status applies.

What is ART27.13?

ART27.13 is a synthetic benzimidazole-derived dual cannabinoid receptor agonist (CB1 and CB2) developed originally by AstraZeneca and licensed to Artelo Biosciences (NASDAQ: ARTL). It is designed with high peripheral selectivity — meaning it activates cannabinoid receptors outside the central nervous system — in order to stimulate appetite and preserve lean body mass in patients with cancer-related anorexia-cachexia syndrome (CACS) while avoiding the CNS-mediated psychoactive and adverse effects commonly associated with cannabis-based medicines. As of mid-2026, the compound remains investigational with no approved use.

How it works

ART27.13 acts as a dual agonist at peripheral CB1 and CB2 G-protein-coupled receptors (GPCRs). Its molecular design restricts CNS penetration, so receptor activation is concentrated in peripheral tissues including gut, muscle, and immune compartments. CB1 agonism in the periphery is understood to contribute to appetite and metabolic signaling; CB2 agonism has been associated in preclinical work with attenuation of cancer-cachexia-induced skeletal muscle myotube degeneration. The compound thus attempts to decouple the appetite-stimulating and muscle-preserving activity of cannabinoid pharmacology from psychoactivity and central adverse effects.

Background & history

ART27.13 was originally synthesized and developed at AstraZeneca before being licensed out. Artelo Biosciences, a small-cap clinical-stage company focused on cannabinoid-related therapeutics, subsequently advanced it into clinical development targeting cancer anorexia-cachexia syndrome — a condition with no currently FDA-approved treatment. The Cancer Appetite Recovery Study (CAReS) trial opened across 18 sites in five countries under EudraCT-2020-000464-27. Phase 1b data were followed by a Phase 2 dose-expansion. In September 2025, Artelo presented positive interim Phase 2 data at the Cancer Cachexia Society Conference. In March 2026, Artelo announced exploration of ART27.13 as a companion therapy to GLP-1 receptor agonists for weight loss and lean body mass preservation, and noted a fully funded third-party glaucoma trial investigating peripheral cannabinoid receptor biology in ocular pressure modulation.

What the research says

Evidence base is early-stage and should be interpreted cautiously. Preclinical: CB2 agonism was shown to prevent cancer-cachexia-induced human skeletal muscle myotube degeneration in vitro (PubMed: 38004445, Pharmaceuticals, November 2023). Phase 1b CAReS (27 patients): well tolerated up to 650 µg/day; 64% of patients achieved weight stabilization or gain by day 28; no dose-limiting toxicities. Interim Phase 2 CAReS (highest-dose cohort, 1,300 µg/day): mean weight gain of +6.38% over 12 weeks versus -5.42% in the placebo group, representing approximately a 12 percentage-point differential; lean body mass at 4 weeks increased +4.23% on active treatment versus -3.15% on placebo; activity levels also improved. Tolerability was maintained across all tested doses through 12 weeks with no fatal treatment-related adverse events. These are interim data from a relatively small clinical trial; confirmatory evidence from larger, completed, peer-reviewed Phase 2/3 trials is not yet available. The GLP-1 companion therapy indication and glaucoma application remain at exploratory or early-trial stage with essentially no published clinical data as of this writing.

Reported effects

Appetite stimulation via peripheral CB1 receptor agonism (observed in Phase 1b/2 cancer cachexia patients)
Attenuation of lean body mass loss in cancer-related cachexia (interim Phase 2 data)
Skeletal muscle myotube protection against cancer-cachexia-induced degeneration (preclinical/in vitro, CB2 mechanism)
Activity level improvement in cancer cachexia patients (interim Phase 2 signal)
Peripheral selectivity: no significant CNS side effects observed in trials to date
Potential for intraocular pressure modulation via peripheral CB receptor activity (fully exploratory, early-stage trial only)
Possible lean body mass preservation as GLP-1 companion therapy (announced March 2026; no clinical data published)

Dosing & administration (informational)

Published trial literature reports dose escalation from approximately 650 µg/day (Phase 1b) to 1,300 µg/day (Phase 2 highest-dose cohort), administered in the context of a controlled clinical trial with medical monitoring in cancer patients. These figures are provided for informational reference only and do not constitute a dosing protocol. No dosing information applicable to self-administration exists or should be inferred from trial data. Consult a licensed clinician for any clinical question.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No dose-limiting toxicities observed through Phase 1b (up to 650 µg/day) or interim Phase 2 (up to 1,300 µg/day)
No fatal treatment-related adverse events reported through 12 weeks in the CAReS trial
Peripheral selectivity design achieved its CNS-sparing target: no significant psychoactive or central cannabinoid side effects reported
Safety data derive from small patient numbers with advanced cancer; long-term or population-wide safety is unknown
Trials conducted in oncology populations with advanced disease; safety profile in healthy individuals or other indications is not established
Not approved for human use outside clinical trials; self-administration outside a trial has no safety or dosing data to support it
Interaction profile with chemotherapy agents and other oncology treatments not fully characterized in published data

Drug & supplement interactions

N
o
p
u
b
l
i
s
h
e
d
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
a
v
a
i
l
a
b
l
e
f
o
r
A
R
T
2
7
.
1
3
b
e
y
o
n
d
w
h
a
t
h
a
s
b
e
e
n
r
e
p
o
r
t
e
d
i
n
c
i
d
e
n
t
a
l
l
y
i
n
c
a
n
c
e
r
t
r
i
a
l
p
o
p
u
l
a
t
i
o
n
s
r
e
c
e
i
v
i
n
g
c
o
n
c
u
r
r
e
n
t
o
n
c
o
l
o
g
y
t
r
e
a
t
m
e
n
t
.
C
a
n
n
a
b
i
n
o
i
d
r
e
c
e
p
t
o
r
a
g
o
n
i
s
t
s
a
s
a
c
l
a
s
s
m
a
y
i
n
t
e
r
a
c
t
w
i
t
h
C
Y
P
4
5
0
-
m
e
t
a
b
o
l
i
z
e
d
d
r
u
g
s
;
h
o
w
e
v
e
r
,
s
p
e
c
i
f
i
c
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
f
o
r
A
R
T
2
7
.
1
3
h
a
v
e
n
o
t
b
e
e
n
p
u
b
l
i
s
h
e
d
.
C
o
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
w
i
t
h
G
L
P
-
1
r
e
c
e
p
t
o
r
a
g
o
n
i
s
t
s
i
s
u
n
d
e
r
e
x
p
l
o
r
a
t
o
r
y
i
n
v
e
s
t
i
g
a
t
i
o
n
b
u
t
n
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
p
u
b
l
i
s
h
e
d
.
D
u
e
t
o
t
h
e
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
s
t
a
t
u
s
a
n
d
e
x
t
r
e
m
e
l
y
l
i
m
i
t
e
d
l
i
t
e
r
a
t
u
r
e
,
i
n
t
e
r
a
c
t
i
o
n
p
o
t
e
n
t
i
a
l
w
i
t
h
a
n
y
d
r
u
g
c
l
a
s
s
c
a
n
n
o
t
b
e
r
e
l
i
a
b
l
y
c
h
a
r
a
c
t
e
r
i
z
e
d
.

Who should avoid it

Self-administration outside an approved clinical trial — no safety net exists
Use in pregnancy or lactation — no data; cannabinoid pharmacology carries established developmental risk signals
Sourcing from gray-market or research-chemical vendors — compound is not commercially manufactured for non-trial use
Conflating with recreational synthetic cannabinoids — ART27.13 is structurally and pharmacologically distinct from JWH-series or other illicit synthetic cannabinoids
Assuming approved-drug standards apply — no regulatory approval exists in any jurisdiction
Interpreting interim Phase 2 data as proof of efficacy — trial is ongoing and results are preliminary

How it is commonly combined

No published stacking or combination-therapy data exist outside the clinical trial context. Artelo has announced investigation of ART27.13 as a companion to GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) to address GLP-1-associated lean body mass loss, but this is an exploratory announcement as of early 2026 with no published clinical trial results. Any combination use remains entirely investigational.

Legal & regulatory. Investigational drug — unapproved by the FDA. ART27.13 is currently in Phase 1/2 clinical development and has no approved indication in the United States or elsewhere. It is not legally available for human use outside of an approved clinical trial protocol. No OTC, supplement, or gray-market status applies.

Quality & harm reduction

Safer, legal alternative we recommend

Big Berb Energy. For a natural approach to the same metabolic/blood-sugar goal, our Berberine is a well-studied legal supplement.

See our recommended pick

Find ART27.13 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is ART27.13 the same as medical cannabis or a synthetic cannabinoid like Spice/K2?

No. ART27.13 is a structurally distinct benzimidazole-class synthetic cannabinoid receptor agonist with high peripheral selectivity and is unrelated to illicit synthetic cannabinoids such as the JWH series or those found in Spice/K2 products. It was developed under pharmaceutical standards and is not available outside controlled clinical trials.

Can I get ART27.13 for cancer cachexia treatment right now?

Not outside of an approved clinical trial. ART27.13 is an investigational drug with no FDA or EMA approval. Participation in the CAReS trial or any successor protocol would require referral and eligibility screening at a participating site. Consult your oncologist.

What is the recommended dose?

No dose recommendation can be made here. The trial has explored doses up to 1,300 µg/day in a controlled clinical setting with medical monitoring. These are research parameters, not a protocol for self-administration. A clinician familiar with the trial data is the appropriate source for any dosing question.

How confident can we be in the Phase 2 results?

The interim Phase 2 data show a numerically meaningful differential in weight and lean body mass compared to placebo, but these are interim results from a relatively small trial. They have not yet been published in a peer-reviewed journal (as of the available evidence base), and the trial is ongoing. Cautious interpretation is warranted pending full trial completion and independent review.

What makes ART27.13 different from dronabinol (Marinol) for appetite stimulation?

Dronabinol is a synthetic THC analogue that acts centrally, producing psychoactive effects and CNS adverse effects. ART27.13 is designed for peripheral CB1/CB2 selectivity, specifically to avoid CNS penetration and associated psychoactivity. The clinical significance of this distinction in the cachexia setting has not been directly compared in head-to-head trials.

Is there a connection to GLP-1 drugs like semaglutide?

Artelo announced in March 2026 that it is exploring ART27.13 as a companion therapy to GLP-1 receptor agonists, on the hypothesis that ART27.13's lean body mass-preserving mechanism could offset the muscle loss sometimes associated with GLP-1-driven weight reduction. This remains an early-stage exploratory program with no published clinical data.

References & further reading

PubMed: 38004445 — CB2 agonism and cancer-cachexia-induced skeletal muscle myotube degeneration (Pharmaceuticals, November 2023)
ClinicalTrials.eu / EudraCT: EudraCT-2020-000464-27 — Cancer Appetite Recovery Study (CAReS); ART27.13 in cancer-related anorexia and weight loss
PubMed / PMC: search 'cachexia wasting chronic illness regulatory clinical trial' — PMC12658287 (review context)
ClinicalTrials.gov: search 'ART27.13 cachexia anorexia cancer' for any registered US-arm equivalents
GlobeNewswire: Artelo Biosciences ART27.13 interim Phase 2 CAReS data, September 2025 press release (no DOI; primary source is conference presentation)